Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 11/20 | 0.47 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.43 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13041636 | 0.94 | C5AR1 (0.45) | C5AR1RAMP1CALCRLOPRM1OPRK1 | |
| SCHEMBL26661186 | 0.78 | SMN1; SMN2 (0.39) | ALDH1A1HTT | |
| SCHEMBL13015326 | 0.78 | BRD4 (0.42) | OPRM1OPRK1OPRL1PARP1ALDH1A1 | |
| SCHEMBL13041646 | 0.77 | MAPK1 (0.47) | C5AR1ALDH1A1 | |
| SCHEMBL13041632 | 0.77 | IDH1 (0.37) | C5AR1RAMP1CALCRLPARP1PARP2 | |
| SCHEMBL13041641 | 0.75 | BRD4 (0.41) | OPRM1OPRK1OPRL1PARP1ALDH1A1 | |
| SCHEMBL13041645 | 0.74 | C5AR1 (0.46) | C5AR1 | |
| SCHEMBL13041629 | 0.74 | SMN1; SMN2 (0.36) | C5AR1RAMP1CALCRLALDH1A1 | |
| SCHEMBL13041639 | 0.73 | PARP1 (0.43) | RAMP1CALCRLOPRM1OPRK1OPRL1 | |
| SCHEMBL13041644 | 0.72 | OPRL1 (0.42) | OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | C5AR1 265/4885RAMP1 3380/4885CALCRL 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.